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A Self{Designing Rule for Clinical Trials with
Arbitrary Response Variables
Abstract. For testing one{sided but also two{sided hypotheses concerning several
treatment arms in group sequentially performed clinical trials with arbitrary out-
come variables, a general learning method is considered that allows for a complete
self{designing of the study. All information available prior to a stage is used for
estimating the sample size and the weight for the next step. In 'using up' the vari-
ance, the test statistic is built in a bounded nite but random number of stages to
test just once the null{hypothesis on rejecting.
1 Introduction
In a recent paper L. Fisher [1] introduces in a general setting for normal variables
with known variances self{designing trials, for which Shen and L. Fisher [2] with
regard to a one{sided hypothesis give a concrete proposal for building the test
statistic. There the sequence of sample sizes is xed prior to the beginning of the
study, although in [1] there is already pointed out that this can be chosen adaptively
using information prior to the respective stage. One continues to assign groups of
subjects until the variance of the test statistic is 'used up'. Related for two{stage
procedures or relative updating within one stage are [3], [4], [5], [6], [7], [8]. The
aim of the self{designing procedures [1], [2] is not to test the null{hypothesis on a
rejection after each stage like for instance in the classical group sequential trials,
cf. [9], [10] and references given there.
An adaptive procedure designed for up to two interim analyses is given by Bauer
and Kohne [11] for a general setting by use of p{values related to the tests carried
out at each stage, which then are combined by R. A. Fisher's method, cf. [12] and
also [13].
In the present paper we employ the inverse normal transformation of the p{values
suiting so under the null{hypothesis to the assumptions of L. Fisher's [1] main
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result. In [14] this p{value transformation is taken in connection with the classical
group sequential trials.
By a reformulation of the original hypothesis also two{sided cases can be considered
for arbitrary response variables in several treatment arms.
A general learning rule for completely self{designing trials is presented below which
at each stage adaptively estimates the sample size and the weight associated to that
stage upon all prior data knowledge.
2 The basic procedure
In a clinical trial let corresponding to a medication i be x
i
an outcome variable
with mean #
i
= Ex
i
, i = 1 ; : : : ; I . Denote
 =
I
X
i=1
 
#
i
  (1=I) 
I
X
j=1
#
j
!
2
;
then the two{sided test problem H
0;#
: #
1
= : : : = #
I
vs. H
1;#
: #
i
1
6= #
i
2
, i
1
6= i
2
,
for at least two i
1
; i
2
2 f 1; : : : ; Ig, becomes equivalent to the one{sided testing of
H
0
:  = 0 vs. H
1
:  > 0;
for instance with the known homogeneity tests. In the case of I = 2 and e.g. i = 1:
verum, i = 2: placebo, for a one{sided comparison one puts  = #
1
 #
2
. Note that
in the general formulation here #
i
may represent a probability if the trial deals with
binary variables. The study is formally divided into an innite number of disjoint
study parts: stp(1), : : : , stp(k), : : : , and it is the aim of a designing rule, that of
those only a nite number, say K, has to be carried out really.
In stp(k) n
k
patients are randomized across the I treatment groups, each con-
sisting so of n
ik
patients,
P
I
i=1
n
ik
= n
k
. Upon their responses x
ik;1
; : : : ; x
ik;n
ik
,
i = 1 ; : : : ; I, we test in stp(k) H
0
vs. H
1
by a, { with respect to H
0
and H
1
one{
sided {, test statistic T
k
, where large values of T
k
may lead to a rejection of H
0
.
Under H
0
let T
k
have a continuous distribution function F
k;0
(otherwise the results
are known to tend to be usually somewhat conservative), then the p{values
p
k
= 1  F
k;0
(T
k
)
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are uniformly distributed on the interval (0; 1), such that
z
k
= 
 1
(1  p
k
)
is standard normally distributed, z
k
H
0
 N(0; 1), where 
 1
denotes the inverse of
the N(0; 1){distribution function , cf. [12].
For a quantity a to be used in or for stp(k) let us introduce the notation
a = a^fk   1g; i. e. a = a^fstp(0), stp(1), : : : , stp(k   1)g;
to indicate that a is determined or estimated upon all the knowledge obtained in
the previous study parts before the beginning of stp(k), where stp(0) may denote
the prior information, implying a^f0g to be in any case a constant in the present
trial.
Dening now an innite sequence of nonnegative weights w
1
; : : : ; w
k
; : : : , such that
with probability one under H
0
there exists a nite (random) K with
K
X
k=1
w
2
k
=
1
X
k=1
w
2
k
= 1 ; where w
k
= w^fk   1g;
then by theorem 1 of L. Fisher [1] we can deduce, that under H
0
the statistic
Z =
P
1
k=1
w
k
 z
k
is standard normally distributed,
Z =
K
X
k=1
w
k
 z
k
=
1
X
k=1
w
k
 z
k
H
0
 N(0; 1):
That means, at given size 
G
the null{hypothesisH
0
is rejected, if Z > 
 1
(1  
G
).
Furthermore, if the sample sizes n
k
are determined upon data{knowledge from
the previous study parts, this does not inuence under H
0
the distribution of
the p{values p
k
, or of z
k
, and even not the independence of p
k
1
, p
k
2
, or z
k
1
, z
k
2
,
k
1
6= k
2
; cf. also the respective extensive discussions by L. Fisher [1], Proschan and
Hundsberger [8], Bauer and Kohne [11]. Hence the statements above remain valid,
if we allow: n
k
= n^fk   1g.
In the case of multiple endpoints, i. e. with x
i
a random vector, a multivariate
extension is provided by putting  =
P
n
i=1
b
t
i
b
i
with b
i
= ( #
i
  (1=I) 
P
I
j=1
#
j
) and
b
t
i
the transpose of the vector b
i
.
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3 A general rule for completely self{designing
The distributions of x
1
; : : : ; x
I
might depend on further parameters  
1
; : : : ;  
`
,
for example variances (and correlations in a multivariate setting), and denote
 = (  
1
; : : : ;  
`
), analogously # = ( #
1
; : : : ; #
I
). For given Type I and II error
rates  and  let in dependence on the involved test statistic T a sample size
spending function S = S
T
be dened, such that by
n = S(;  j #;  ;  6= 0)
the smallest, nite n is delivered such that in a sample of size n the test of H
0
by T
has at least level  and power 1 . For example in the simple originally two{sided
normal case of H
0;#
with I = 2 this is the well known formula
n = n
1
+ n
2
= 2  f (
 1
(1  =2) + 
 1
(1  )) 
p
2  

(#
1
  #
2
)g
2
with 
2
the common variance of x
1
, x
2
, respectively n = [ n
1
+ 1] + [ n
2
+ 2] with
n
1
= n
2
, where [m] denotes the largest natural number less than m.
The self{designing rule R is characterized now by the sept{tuple
R = R(
G
; 
G
; n
1
; w
1
; 
g
;  ;
L
);
that consists of the global Typ I and II error rates 
G
and 
G
, e.g. 
G
= 0 :05,

G
= 0 :1, the starting congurationn
1
= n^f0g, w
1
= w^f0g  1 for stp(1), the Type
II error rate 
g
 
G
for generating the sequential sample sizes n
k
= n^fk   1g,
e.g. 
g
= 0 :2 or larger, where
g
can also be dened in dependence of k, 
g
= 
g
(k),
further  > 0 is a lower bound for the weights w
k
,  < w
1
, e.g.  = 0 :1 or
p
0:1,
and 
L
denes by 
 1
(
L
) a lower bound for
P
k
j=1
z
j
=
p
k, i.e. if that statistic falls
below the bound, H
0
is early accepted, e.g. 
L
= 0 :6, or
L
= 
L
(k), increasing
with k starting e.g. even in zero, but cf. [2] for a detailed discussion of that point.
Extending and modifying the basic idea of Shen and L. Fisher [2], given for the
one{sided normal case with known variances and the whole sequence of sample sizes
xed prior to the beginning of the trial, the rule R procedure is derived as follows:
Let w
j
, p
j
, z
j
be given for j = 1 ; : : : ; k  1, with Z
k 1
=
P
k 1
j=1
w
j
 z
j
, then if for
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stp(k) in the equation
P(Z
k 1
+
r
1 
X
k 1
j=1
w
2
j
 bz
k
> 
 1
(1  
G
)




# =
^
#fk   1g;
 =
^
 fk   1g;  =
^
fk   1g 6 = 0) = 1   
we would claim  = 
G
, so by putting w
k
= w
k;G
=
q
1 
P
k 1
j=1
w
2
j
we would
have
P
k 1
j=1
w
2
j
+ w
2
k;G
= 1 with Z
k;G
= Z
k 1
+ w
k;G
 z
k
(
G
) our nal statistic, that
would hold level 
G
and power 1   
G
, conditionally under
^
#fk   1g,
^
 fk   1g,
^
fk  1g > 0; note that z
k
(
G
) is obtained upon n
k
(
G
) observations in stp(k), see
below. In this way by letting 
g
(k) go to 
G
if k goes to some K, the termination
of the study can be accelerated.
Now usually we choose 
g
> 
G
in order to give the parameter estimates more
chances to stabilize. Putting
1  bp
k
= (bz
k
) = 
"


 1
(1  
G
)  Z
k 1

r
1 
X
k 1
j=1
w
2
j
#
and
S
k
(; ) = S(;  j
^
#fk   1g;
^
 fk   1g;
^
fk   1g 6 = 0) ;
we dene potential sample size numbers m
k
and M
k
for stp(k) by:
m
k
= S
k
( bp
k
; 
g
); and M
k
= S
k
( bp
k
; 
G
):
At the power 1   
G
these sample sizes would in stp(k) lead to the levels c
k
(m
k
)
and c
k
(M
k
) , respectively, given by the following implicit equations:
m
k
= S(c
k
(m
k
); 
G
); and M
k
= S(c
k
(M
k
); 
G
); m
k
;M
k
given:
Introducing now recursively the weight function
W (k) =
r
1 
X
k 1
j=1
W (j)
2


 1

1 
c
k
(m
k
)
2


 1

1 
c
k
(M
k
)
2

; W (1) = w
1
 1 given;
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we set the control parameters weight w
k
and sample size n
k
for stp(k) as follows:
w
k
=
8
<
:
W (k) ; if W (k)  ;
q
1 
P
k 1
j=1
w
2
j
; if W (k) < ;
and
n
k
=
(
m
k
; if W (k)  ;
M
k
; if W (k) < :
If W (k) <  , then putk = K and the trial stops after stp(K), i.e. w
K+j
= 0, for
j = 1 ;2; : : : .
Then we get with the n
k
patients in stp(k) by the test statistic T
k
the p{value p
k
,
yielding the intermediate result Z
k
= Z
k 1
+ w
k
 
 1
(1   p
k
), or for k = K the
nal result Z
K
.
A generally longer running sequence of study parts we obtain if in the formula for
W (k) we replace the second factor by
p
m
k
=M
k
, or by the ratio

 1
(F
k;0
(E T
k
(m
k
)))=
 1
(F
k;0
(E T
k
(M
k
))), where E T
k
(n) denotes the expecta-
tion of T
k
with n patients in stp(k) under # =
^
#fk   1g and  =
^
 fk   1g.
Note that the random nal number K of study parts to be really performed is
bounded in any way by K < 2 + (1  w
2
1
)=
2
.
4 An illustrative example
Let us consider two medications with binary outcome variables, and #
1
, #
2
be for
instance the expected cure rates. We are interested in the two{sided test problem:
H
0;#
: #
1
= #
2
vs. H
1;#
: #
1
6= #
2
;
becoming one{sided by:
H
0
:  = ( #
1
  #
2
)
2
= 0 vs. H
1
:  > 0:
Having at the beginning no real information, only a guess that not less than 200 pa-
tients would be involved, we choose the starting conguration as n
1
= n
11
+ n
21
= 40
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patients, to be equally randomized, as in the following stages, too, across the two
treatment groups, and the weight w
2
1
= 40 =200 = 0:2. The other chosen control
parameters can be seen in the rule
R = R(
G
= 0 :05; 
G
= 0 :1; 40;
p
0:2; 
g
= 0 :25; = 0 :1;
L
= 0 :6):
To keep the representation here more self{contained, we use the well known Arcus{
Sinus Formula as approximate sample size n spending function S,
n = (
 1
(1  =2) + 
 1
(1  ))
2
=
2
; where  = sin
 1
(
p
#
1
)  sin
 1
(
p
#
2
);
yielding for given n, ,  the explicit representation for the solution b(n) by

 1
(1  b(n)=2) =
p
n  
2
  
 1
(1  ):
Now instead of dening somehow the p{value of a two{sided test{statistic for testing
H
0;#
, we take the 
2
1
{test statistic for (22){tables with n
k
subjects as test statistic
T
k
in stp(k), being one{sided with respect to H
0
vs. H
1
.
Hence we get in stp(k):
1  p
k
= 
2
1
(T
k
) = 2 (
p
T
k
)  1; and z
k
= 
 1
(1  p
k
):
Denote
c
#
ik
= (number of cured patients in stp(k)=n
ik
) the estimate of #
i
, i = 1 ;2,
in stp(k), for simplicity here assumed to be constantly across all stp's equal to:
b
#
1
= 0 :7 and
b
#
2
= 0 :5. So withn
1
= 40, w
2
1
= 0 :2 we get in stp(1): T
1
= 1 :67,
1   p
1
= 0 :8,z
1
= 0 :84; Z
1
= 0 :376, and therefore for stp(2): 1  bp
2
= (1:43),
1   bp
2
=2 = 0 :96,m
2
= 164, M
2
= 256, w
2
= 0 :89 1:28=1:92 = 0:59. Hence with
n
2
= 164 patients in stp(2) we obtain: T
2
= 6 :83, 1 p
2
= 0 :99,z
2
= 2 :33,Z
2
= 1 :75,
and therefore for stp(3): 1   bp
3
= (  0:15),m
3
= (0 :6 + 0 :68)
2
=0:036 = 46,
M
3
= (0 :6 + 1 :28)
2
=0:036 = 98, and W (3) = 0:67  0:035=0:598 = 0:039 <  , so
w
3
= 0 :67,n
3
=M
3
= 98, giving in stp(3) the result: T
3
= 4 :1 orz
3
= 1 :75.
Thus the nal test statistic takes on the form: Z
3
= 0 :4584+0 :592:33+0:67 1:77
= 2 :94 = 
 1
(0:9984), achieved with 40+164+98 = 302 patients. At rst we may
wonder about the weights in relation to the respective number of patients. But this
is a characteristic of the learning scheme: after stp(1) the algorithm is cautious in
giving a weight to the second stage, however after the big stp(2) it has learned that
8
the parameter estimates remained as expected and so the next stage can get the
rest of possible weight.
Secondly we see that we have not much payed for the learning in form of the number
of patients to be enclosed: in a xed sample size plan we would have calculated,
with the same approximate formula, 292 necessary patients, only 10 less than above,
if the parameter dierence  would have been known in advance. So we can get
the impression that our learning algorithm is on the one hand cautious in spending
high weights too early, and on the other hand it uses patients sparingly.
5 Conclusion
We propose a group sequential method for a complete self{designing of clinical
trials as basically introduced by L. Fisher [1]. The termination of the whole trial
is steered by a sequentially built weighting function until the variance of the test
statistic is 'used up'. Based on the non{parametric character of the p-values our
method applies to a wide range of situations.
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